FRM
CLVS

Fox Run Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Fox Run Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-19,830
Closed -$134K – 356
2020
Q2 		$134K Buy
+19,830
New +$150K 0.18% 236
2019
Q1 		– Sell
-44,774
Closed -$804K – 751
2018
Q4 		$804K Buy
44,774
+18,460
+70% +$377K 0.43% 22
2018
Q3 		$773K Buy
+26,314
New +$1.02M 0.34% 42
2018
Q2 		– Sell
-15,982
Closed -$844K – 972
2018
Q1 		$844K Buy
+15,982
New +$932K 0.2% 128
2016
Q3 		– Sell
-11,200
Closed -$154K – 744
2016
Q2 		$154K Buy
+11,200
New +$164K 0.07% 474

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's CLVS Position: Q3 2020 in Review

Fox Run Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2020, closing a stake of 19,830 shares — an estimated $134K sold.

Fox Run Management first reported a position in CLVS in Q2 2016 and held it in 5 quarters. The position peaked at $844K in Q1 2018. 169 funds tracked by Wall St. Rank hold CLVS as of Q3 2020.

  • Fox Run Management reported no remaining Clovis Oncology, Inc. position as of Q3 2020 after selling out during the quarter.
  • Fox Run Management sold 19,830 Clovis Oncology, Inc. shares in Q3 2020, an estimated $134K.
  • Fox Run Management first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 5 quarters.
  • Fox Run Management's Clovis Oncology, Inc. position peaked at $844K in Q1 2018.
  • 169 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2020.

Based on Fox Run Management's 13F filing for Q3 2020, filed 29 Oct 2020.